What ICD‑10‑CM codes correspond to an adult patient with type 2 diabetes mellitus, elevated vitamin B12, hyperlipidemia, and who is taking low‑dose aspirin, ergocalciferol, fish‑oil supplement, glimepiride, a lisinopril/hydrochlorothiazide combination, metoprolol tartrate, and nifedipine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10-CM Codes for Medication Coverage and Laboratory Testing

For this diabetic patient with hypertension, hyperlipidemia, and elevated B12 on multiple cardiovascular medications, use the following ICD-10-CM codes to ensure comprehensive coverage:

Primary Diagnosis Codes

Diabetes Mellitus

  • E11.9 - Type 2 diabetes mellitus without complications 1, 2
  • E11.65 - Type 2 diabetes mellitus with hyperglycemia (if applicable based on glucose control) 1
  • E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease (if albuminuria or reduced eGFR present) 2, 3
  • E11.36 - Type 2 diabetes mellitus with diabetic cataract (if retinopathy screening reveals complications) 3

Cardiovascular Conditions

  • I10 - Essential (primary) hypertension 2, 4
    • This code justifies lisinopril/HCTZ, metoprolol, and nifedipine 5
  • I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris 1, 6
    • This code supports aspirin for secondary prevention if cardiovascular disease is documented 1, 6
  • Z79.82 - Long-term (current) use of aspirin 1, 6

Lipid Disorders

  • E78.5 - Hyperlipidemia, unspecified 7, 8
    • This is the primary code for hyperlipidemia and justifies statin therapy consideration 7
  • E78.2 - Mixed hyperlipidemia (if both elevated cholesterol and triglycerides) 8
  • E78.1 - Pure hyperglyceridemia (if triglycerides are the predominant abnormality) 8

Vitamin Abnormalities

  • E53.8 - Deficiency of other specified B group vitamins 2
    • Use this for elevated B12 monitoring, though elevated B12 doesn't have a specific ICD-10 code; this allows tracking
  • E55.9 - Vitamin D deficiency, unspecified 2
    • This justifies ergocalciferol (vitamin D2) supplementation 2

Medication-Specific Justification Codes

For Aspirin (81mg)

  • Z79.82 - Long-term (current) use of aspirin 6
  • I25.10 or cardiovascular disease code if documented 1, 6
  • For primary prevention in diabetes: Use E11.9 with I10 (diabetes with hypertension as additional risk factor) 1, 3, 6

For Glimepiride (Sulfonylurea)

  • E11.9 - Type 2 diabetes mellitus without complications 9, 10
  • E11.65 - Type 2 diabetes mellitus with hyperglycemia (if A1C elevated) 1, 10

For Lisinopril/HCTZ Combination

  • I10 - Essential hypertension 2, 4, 5
  • E11.22 - Type 2 diabetes with diabetic chronic kidney disease (ACE inhibitors are first-line for diabetic nephropathy) 2, 3, 5
  • I13.10 - Hypertensive heart and chronic kidney disease without heart failure (if both conditions present) 2

For Metoprolol

  • I10 - Essential hypertension 4
  • I25.2 - Old myocardial infarction (if history of MI; beta-blockers should be continued for at least 2 years post-MI) 2

For Nifedipine (Calcium Channel Blocker)

  • I10 - Essential hypertension 4
  • Use when multiple antihypertensive agents are required to reach target BP <130/80 mmHg in diabetic patients 2, 4

For Fish Oil Supplement

  • E78.1 - Pure hyperglyceridemia (if triglycerides elevated) 8, 11
  • E78.5 - Hyperlipidemia, unspecified 8

Laboratory Testing Justification Codes

For Lipid Panel

  • E78.5 - Hyperlipidemia, unspecified 1, 3, 8
  • E11.9 - Type 2 diabetes (annual lipid screening recommended) 1, 2, 3

For Hemoglobin A1C

  • E11.9 or E11.65 - Type 2 diabetes mellitus 1, 2, 3

For Comprehensive Metabolic Panel (CMP)

  • E11.9 - Type 2 diabetes 1, 3
  • I10 - Hypertension (monitoring electrolytes on HCTZ) 5
  • Z79.4 - Long-term (current) use of insulin (if applicable) 1
  • N18.9 - Chronic kidney disease, unspecified (monitoring renal function on ACE inhibitor) 2, 3, 5

For Urine Albumin-Creatinine Ratio

  • E11.9 - Type 2 diabetes (annual screening recommended) 2, 3
  • E11.22 - Type 2 diabetes with diabetic chronic kidney disease (if previously abnormal) 3

For Vitamin B12 Level

  • E53.8 - Deficiency of other specified B group vitamins 2
  • E11.9 - Type 2 diabetes (monitoring for metformin-associated B12 deficiency if on metformin) 10

For 25-Hydroxy Vitamin D Level

  • E55.9 - Vitamin D deficiency, unspecified 2
  • Justifies ergocalciferol supplementation monitoring 2

Critical Coding Considerations

Multiple antihypertensive medications require documentation that blood pressure targets are not met with monotherapy 2, 4. The combination of lisinopril/HCTZ, metoprolol, and nifedipine indicates resistant hypertension or target BP <130/80 mmHg for diabetic patients 2, 4.

For aspirin in primary prevention, ensure documentation of 10-year cardiovascular risk >10% or presence of additional risk factors (hypertension qualifies) 1, 3, 6. For secondary prevention, document established cardiovascular disease 6.

Statin therapy should be strongly considered for this patient with diabetes and hyperlipidemia, regardless of baseline LDL cholesterol levels 7, 1, 7. If not prescribed, document the clinical reasoning 1, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.